4 Pharmaceutical Stocks to Buy Now

Popular Posts: 9 Oil and Gas Stocks to Buy NowBiggest Movers in Energy Stocks Now – CHK KOG CLD PXDHottest Technology Stocks Now – GTAT N WDAY AMAT Recent Posts: Biggest Movers in Healthcare Stocks Now – LCI STJ CYH SIRO Biggest Movers in Financial Stocks Now – ENV KCG MFC CIM Biggest Movers in Technology Stocks Now – CGNX ADVS SYNA HIMX View All Posts 4 Pharmaceutical Stocks to Buy Now

This week, four pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. () is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. .

This week, Watson Pharmaceuticals () is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. .

This week, Impax Laboratories, Inc.’s () ratings are up from a C last week to a B. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. .

Mylan () shows solid improvement this week. The company’s rating rises from a B to an A. Mylan is a global generic and specialty pharmaceuticals company. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.